Skip to main content
. 2020 Dec 10;11:605949. doi: 10.3389/fpsyt.2020.605949

Figure 1.

Figure 1

Qualitative patterns for the biomarker-dependent differentiation of clinical outcome between GG-treated and not GG-treated (TAU) subjects. The treatment effect is determined by the ratio of the HAMD-21 at week 2 to that at baseline. A value of 1 refers to no change in HAMD-21; higher values to worsening; and lower values to improvement. Lower systolic blood pressure is related to lesser improvement in the TAU group, but larger improvement in the GG, which leads to a larger differentiation between the groups with lower systolic blood pressure. GG, Glycyrrhiza glabra add-on; TAU, treatment as usual.